NCT06826872View on ClinicalTrials.gov

Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

PHASE2RecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

October 8, 2025

Study Completion Date

December 30, 2025

Conditions
Hypertension, EssentialCardiovascular DiseasesCardiology
Interventions
DRUG

SPC 1001 Mid2

low-dose combination therapy

DRUG

SPC 2002

low-dose combination therapy

DRUG

SPC 2003

low-dose combination therapy

DRUG

SPC 2004

low-dose combination therapy

Trial Locations (1)

06135

RECRUITING

CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea, Seoul

All Listed Sponsors
lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY